Publicly traded cancer diagnostics company Oncocyte has used several avenues to fund its growth in recent years. President and CEO Ron Andrews discusses the company's latest capital raises and acquisitions. He talks about the company's use of its at-the-market program, how it works, when it's best deployed, and what the raise from it has enabled to the company to do.
